key: cord-0786339-ch0x1ejd authors: Zhang, Yongjing; Wang, Jue; Hu, Shiling; Xue, Zhuoyin; Wang, Cheng; Wang, Nan title: Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2 date: 2020-12-16 journal: Virology DOI: 10.1016/j.virol.2020.12.001 sha: 1d0926d40f45639af55f36e6e9b0cc0bfa69cd97 doc_id: 786339 cord_uid: ch0x1ejd The SARS-CoV-2 outbreak, began in late 2019, has caused a worldwide pandemic and shows no signs of slowing. Glucocorticoids (GCs), including dexamethasone (DEX), have been widely used as effective anti-inflammatory and immunosuppressant drugs. In this study, seven GCs had no obvious effect on cell viability of angiotensin converting enzyme 2 (ACE2) high expressed HEK293T cells when concentrations were under 10 μM. Molecular docking results revealed that DEX occupied with active binding site of ACE2 of SARS-CoV-2 spike protein. Surface plasmon resonance (SPR) results showed that K(D) value between DEX and ACE2 was (9.03 ± 0.78) e−6 M. Cell membrane chromatography (CMC) results uncovered that DEX had a chromatographic retention. DEX was found out to inhibiting the viropexis into ACE2(h) cells using SARS-CoV-2 spike pseudotyped virus. Therefore, DEX inhibits the entrance of SARS-CoV-2 spike pseudotyped virus into cell by binding to ACE2. Weiss & Murdoch, 2020). The renin-angiotensin-aldosterone system (RAAS) is a significant system 70 managing vasoactive peptides. ACE2, an enzyme that physiologically counters RAAS 71 activation but also functions as a receptor for both SARS viruses . 72 Therefore, studying whether the compound blocks or antagonizes the ACE2 receptor 73 in epithelial cells can help to screen and identify potential drugs that can treat In the present study, SPR and molecular docking were used to detect the binding 81 characteristics of GCs with ACE2 and the RBD of SARS-CoV-2 spike protein. The protocol of ACE2 h /CMC column preparation is as follows (Ma et al., 2017) . 164 In brief, a certain extent number (∼1 × 10 7 ) of well-grown ACE2 h cells were gathered 165 and washed three times by precooled physiological saline. Then ruptured with 30 min 166 ultrasonic in 50 mM Tris-HCl hypotonic solution (pH 7.4) and 3 min homogenization. The suspension of the ruptured cells was then centrifuged for 10 min at 1000 × g, the (Table 1) . Although other GCs can also bind with active residue, such as TRI and FLD bind with 227 ASP30 in ACE2, and FLO with GLN498 in RBD, they cannot interact with both 228 proteins. degree of binding. DEX showed the best affinity with ACE2 than other GCs, the 232 binding constant K D value was (9.03±0.78)e-6 M (Fig.3) . Considering that the interaction between ACE2 and GCs was detected by SPR in 235 a non-bioactive state, we further investigated the interaction by CMC which was a bio retained on ACE2 h -CMC column. So far, we believed that DEX can interected with 285 ACE2. Although the K D between ACE2 and spike protein was much smaller than that 286 between ACE2 and DEX, DEX was preincubated before adding spike protein 287 pseudovirus in this experiment. Plenty of DEX was allowed to bind to ACE2 freely. GC ACE2 RBD of 2019-nCoV spike protein DEX LYS353*, GLY354 GLY496, GLN498* BET THR324, GLY354, ASN330 SER494, GLY496, TYR505 TRI ASP30*, GLN35 TYR449, GLY496 MET THR324, GLY354, ARG357* GLN493, GLY496, TYR505 FLO THR27, GLN76 GLY496, GLN498* FLD ASP30* GLN493, GLY496 HYD THR324, LYS353, GLY354 SER494, GLY496, TYR505 Dual-mixed/CMC model for screening target 353 components from traditional Chinese medicines simultaneously acting on EGFR & 354 FGFR4 receptors A study on 356 infectivity of asymptomatic SARS-CoV-2 carriers Clinical Characteristics of Coronavirus Disease The 362 origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) 363 outbreak -an update on the status Therapeutic glucocorticoids: mechanisms of 366 actions in rheumatic diseases Progress in cell membrane chromatography Dexamethasone in the management of covid -19 Coronavirus breakthrough: dexamethasone is first drug shown to save Pharmacological agents 375 for adults with acute respiratory distress syndrome CD004477 Research and Development on Therapeutic Agents and Vaccines for COVID-19 and 382 Related Human Coronavirus Diseases Genomic characterisation 385 and epidemiology of 2019 novel coronavirus: implications for virus origins and 386 receptor binding Determine equilibrium dissociation 388 constant of drug-membrane receptor affinity using the cell membrane chromatography Drug Therapy, and Mortality in Covid-19 Establishment and 401 validation of a pseudovirus neutralization assay for SARS-CoV-2 Glucocorticoid-induced myopathy Clinical evidence does not support 406 corticosteroid treatment for 2019-nCoV lung injury Dexamethasone in Sars-CoV-2 Patients Genomic and nongenomic effects of glucocorticoids SARS: systematic review of treatment 413 effects A Review of SARS-CoV-2 and the Ongoing Clinical Trials Adjunctive 419 Glucocorticoid Therapy in Patients with Septic Shock González-Martín Dexamethasone treatment for the acute respiratory distress syndrome: a 423 multicentre, randomised controlled trial Clinical 426 Characteristics of 138 Hospitalized Patients With Clinical course and mortality risk of severe COVID-19 Early antiviral treatment 431 contributes to alleviate the severity and improve the prognosis of patients with Structural basis for the 435 recognition of SARS-CoV-2 by full-length human ACE2 A safe and convenient 438 pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for 439 viral entry inhibitors against the novel human coronavirus MERS-CoV